Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review

• Conditions: Urinary Bladder, Overactive
• Interventions: Drug: Intradetrusor Injection of Type-A Botulinum Toxin; Other: Other interventions analyzed according to protocol

• Registration Number: NCT01750645
• Lead Sponsor: Clínica Infantil Colsubsidio

Brief Summary

Overactive bladder is defined as a syndrome composed of urgency, increased urinary frequency, and sometimes urinary incontinence; its etiology may be characterized as neurogenic or non-neurogenic (i.e., idiopathic). This illness has a great impact in quality of life and one of the available treatments is the injection of Botulinum Toxin. This study aims to review the efficacy and safety of type-A Botulinum Toxin in the management of Idiopathic Overactive Bladder. A systematic search was performed in MEDLINE, EMBASE, CENTRAL and LILACS, and the controlled randomized clinical trials were chosen to review with the CONSORT criteria by independent reviewers. Outcomes analyzed were the efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence), adverse events to treatment, change in quality of life and urodynamic measures.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-07
• Primary Completion: 2012-10
• Status Verified: 2012-12
• Study First Submitted: 2012-12-11
• Study First Submitted QC: 2012-12-13
• Last Update Submitted: 2012-12-13
• Study First Posted: 2012-12-17
• Last Update Posted: 2012-12-17
• Study Completion: 2013-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Controlled randomized clinical trials
• Adult patients diagnosed with idiopathic overactive bladder
• Language of the study: english

Exclusion Criteria

• Diagnosis of neurogenic overactive bladder
• Patients under 18 years old
• Use of Type-B Botulinum Toxin as the intervention
• Other types of studies

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Intervention Group	Intradetrusor Injection of Type-A Botulinum Toxin	-
Control Group	Other interventions analyzed according to protocol	-

Primary Outcome Measures

Name	Time	Method
Efficacy of the intervention for relieving the symptoms (urgency, frequency and urgency incontinence)	Minimun follow-up period of 12 weeks

Secondary Outcome Measures

Name	Time	Method
Adverse events to treatment (urinary retention and urinary tract infections)	Minimun follow-up period of 12 weeks
Change in quality of life	Minimun follow-up period of 12 weeks
Change in urodynamic measures	Minimun follow-up period of 12 weeks	Increase in maximum cystometric capacity, first desire to void, normal desire to void, postvoid residual volume, and the presence/abscence of detrusor overactivity.

Trial Locations

Locations (1)

Clínica Infantil Colsubsidio; 🇨🇴 Bogotá DC, Colombia